Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
12 août 2021 08h05 HE
|
Metacrine, Inc.
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin...
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
10 août 2021 09h00 HE
|
Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
Metacrine to Present at 2021 Canaccord Genuity Growth Conference
09 août 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Qu Biologics’ Phase 2 RESTORE trial data presented at 2021 European Crohn’s and Colitis Congress
13 juil. 2021 08h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biotechnology company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn’s and Colitis Organisation (ECCO) 2021 Virtual Congress
06 juil. 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and...
Metacrine to Present at 2021 Jefferies Healthcare Conference
26 mai 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting
19 mai 2021 08h05 HE
|
Metacrine, Inc.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine Accelerates MET409 Clinical Development Milestone and Reports First-Quarter 2021 Results
13 mai 2021 16h05 HE
|
Metacrine, Inc.
• Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021 • Interim data from the...
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
24 févr. 2021 10h00 HE
|
Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...
Qu Biologics Completes $8M Financing
09 déc. 2020 06h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...